Neuland Laboratories
NEULANDLAB · Pharma > Pharmaceuticals & Drugs · Chairman: Davuluri Rama Mohan Rao · MD: Davuluri Saharsh Rao · Listing date: Oct. 14, 2008 · Employees: 1427 · Hyderabad · http://www.neulandlabs.com

Stock Price vs Company Growth
1d
1.7%
1w
0.8%
1m
13.6%
3m
26.9%
6m
0.8%
1y
50.8%
5y
49.7%
10y
35.8%
all
34.8%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 16,759 1.7%
11,500
18,380
Company Overview

Sales
2,023 Cr
Growth: 8.6%
Profit after Tax
364 Cr
Growth: 103.2%
Mid Cap
21,502 Cr
P/E: 59.1x
Industry P/E: 31.1x
Fundamentals

Sales (Cr) ₹ 2,023
Growth 8.6%
EBITDA 28.4%
P/S 10.6x
Dividend 0.1%
P/E 59.1x
Book Value ₹ 1,460
PEG Ratio 6.8x
ROE 21.7%
P/B 11.5x
Shareholding Pattern

Institutions
Malabar India Fund Limited
9.95 %
Malabar Value Fund
4.29 %
Matthews India Fund
2.55 %
Icg Q Limited
1.76 %
Promoters
Ramamohan Rao Davuluri
24.97 %
Davuluri Vijaya Rao
4.78 %
Davuluri Sucheth Rao
2.63 %
Davuluri Saharsh Rao
1.98 %
Davuluri Rohini Niveditha Rao
1.27 %
Others
Mukul Mahavir Agrawal
2.34 %
Kedia Securities Private Limited
1.01 %
Iepf
0.21 %
Increase    Decrease    No change
Company Profile Detailed

Named after Father Nieuwland of Notre dame, Neuland Laboratories was incorporated in 1984 by Dr. D. R. Rao for the manufacture of Salbutamol Sulphate, with mere 40 employees.It has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.
Investors (92)
Followers (2)